Literature DB >> 12605173

Progressive improvement of prognosis for patients with gastric cancer (dynamic stage grouping) with increasing survival interval from initial staging: how much longer can a given survivor expect to live?

Yoshihiro Moriwaki1, Chikara Kunisaki, Shunsuke Kobayashi, Hirofumi Harada, Shinsuke Imai, Yasuhiro Kido, Chitaka Kasaoka.   

Abstract

BACKGROUND: The prognosis in gastric cancer is usually defined at the time of presentation. Prognosis, however, is a variable that alters with time. Once a patient has survived for 1 year, the prognosis will change. This study examines this variable in patients who have survived from 1 to 5 years after operation.
METHODS: Of 1468 patients with gastric cancer, the next 5-year survival (5YS) of patients who already survived for 1, 2, 3, 4, and 5 years after the initial operation was examined, ie, for patients who have survived 1 year, the 5YS (the 6-year survival from operation) was calculated. Similar survival was determined for patients who had survived more than 2, 3, 4, or 5 years and reported according to stage.
RESULTS: In patients who survived 2 years, the next 5YS from that time of patients in stage III a stage was similar to that in stage II, and was similar to the 5YS of patients in stage II at the time of diagnosis. In patients who survived 3, 4, or 5 years, the next 5YS from that time of patients in stage III b and stage III a was similar to that of stage II, and subsequently improved. Similarly, the relationship between stage and survival was disordered subsequently with the passage of time. Similar improvement in survival such that 5YS from the 3rd, 4th, and 5th postoperative year approximated that of the survival of patients at an earlier stage at the time of diagnosis.
CONCLUSIONS: Survival is not only stage-dependent at the time of diagnosis but dependent on the length of survival from the initial operation. Progressive improvement in subsequent 5YS appears to approximate survival of lower-stage disease with the passage of time.

Entities:  

Mesh:

Year:  2003        PMID: 12605173     DOI: 10.1067/msy.2003.95

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Novel operative technique for vagal nerve- and pyloric sphincter-preserving distal gastrectomy reconstructed by interposition of a 5 cm jejunal J pouch with a 3 cm jejunal conduit for early gastric cancer and postoperative quality of life 5 years after operation.

Authors:  Ryouichi Tomita; Katsuhisa Tanjoh; Shigeru Fujisaki
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

2.  Billroth 1 versus Roux-en-Y reconstructions: a quality-of-life survey at 5 years.

Authors:  Souya Nunobe; Abuchi Okaro; Mitsuru Sasako; Makoto Saka; Takeo Fukagawa; Hitoshi Katai; Takeshi Sano
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

3.  Symptom evaluation of long-term postoperative outcomes after pylorus-preserving gastrectomy for early gastric cancer.

Authors:  Souya Nunobe; Mitsuru Sasako; Makoto Saka; Takeo Fukagawa; Hitosho Katai; Takeshi Sano
Journal:  Gastric Cancer       Date:  2007-09-26       Impact factor: 7.370

4.  Characteristics of gastric cancer with esophageal invasion and aspects of surgical treatment.

Authors:  Kohei Wakatsuki; Tomoyoshi Takayama; Masato Ueno; Sohei Matsumoto; Koji Enomoto; Tetsuya Tanaka; Yoshiyuki Nakajima
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

5.  P53 genetic polymorphism of gastric cancer in Korea.

Authors:  Woo Chul Chung; Kang Moon Lee; Bo In Lee; Ji Sung Chun; So Yeon Lee; U-Im Chang; Soo Heon Park; Jin Mo Yang; Kyu Yong Choi; In-Sik Chung
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

6.  Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy.

Authors:  Jin Won Lee; Bandar Ali; Han Mo Yoo; Cho Hyun Park; Kyo Young Song
Journal:  BMC Cancer       Date:  2015-12-23       Impact factor: 4.430

7.  Conditional cause-specific survival after chemotherapy and local treatment for primary stage IV breast cancer: A population-based study.

Authors:  Min Xiao; Pin Zhang
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.